Vetigenics is a clinical-stage animal health biopharmaceutical company committed to advancing targeted antibody therapies for pets from a platform that provides unlimited therapeutic potential. Its proprietary CANIBODY™ technology unlocks faster, more cost-effective, and ethical solutions to develop superior antibodies proven effective in humans with cancer and chronic diseases but created specifically for pets. The company's innovative technology and pioneering expertise in antibody discovery and development are trusted by global animal health partners and the National Cancer Institute. At Vetigenics, we are dedicated to enabling pets to live their best lives. For more details, visit www.vetigenics.com and connect with us on LinkedIn.
